Get started
Author

Christen M. Dillard

Observed names: C Dillard, Christen Dillard, Christen M Dillard, Christen Marie Dillard
Observed institutions: The University of Texas MD Anderson Cancer Center, University of California, Los Angeles, University of California, San Francisco, Rhode Island Hospital, University of Pennsylvania, The University of Texas Health Science Center at Houston
ORCID: 0000-0002-7218-9960
Observed ORCID: 0000-0002-7218-9960
OpenAlex ID: A5009779685
Epithelial Membrane Protein-2 (EMP2) Activates Src Protein and Is a Novel Therapeutic Target for Glioblastoma
2014 · Yu Qin, Maoyong Fu, et al. · Journal of Biological Chemistry · 43
PDF
Reversal of chemosensitivity and induction of cell malignancy of a non-malignant prostate cancer cell line upon extracellular vesicle exposure
2013 · Kiriaki Panagopoulos, Sam Cross-Knorr, et al. · Molecular Cancer · 41
PDF
EMP2 is a novel therapeutic target for endometrial cancer stem cells
2017 · M H Kiyohara, C Dillard, et al. · Oncogene · 37
Racial and ethnic differences in clinical outcomes among patients with multiple myeloma treated with CAR T-cell therapy
2023 · Lauren C. Peres, Laura B. Oswald, et al. · Blood Advances · 29
PDF
EMP2 Is a Novel Regulator of Stemness in Breast Cancer Cells
2020 · Christen Dillard, Meagan Kiyohara, et al. · Molecular Cancer Therapeutics · 21
Racial and Ethnic Differences in Clinical Outcomes Among Multiple Myeloma Patients Treated with CAR T Therapy
2022 · Lauren C. Peres, Laura B. Oswald, et al. · Blood · 10
Pre-Apheresis Prediction of Toxicity and Response in Patients Receiving BCMA-Directed CAR-T for Relapsed/Refractory Multiple Myeloma
2024 · Kai Rejeski, Doris K. Hansen, et al. · Blood · 8
Enhancing the safety of ciltacabtagene autoleucel in relapsed multiple myeloma (MM): Identification of potentially modifiable risk-factors associated with delayed neurotoxicity and non-relapse mortality
2025 · Surbhi Sidana, Brett Reid, et al. · Blood · 7
EMP2 Serves as a Functional Biomarker for Chemotherapy-Resistant Triple-Negative Breast Cancer
2024 · Ann M. Chan, Brian Aguirre, et al. · Cancers · 5
PDF
Cytopenias and infections following ciltacabtagene autoleucel in heavily-pretreated relapsed or refractory multiple myeloma
2025 · Danai Dima, Jennifer M. Logue, et al. · Haematologica · 4
PDF
The Great Masquerader: Syphilis Mimicking Papilledema and Traction Alopecia
2020 · Michelle A McNally, Angela Murira, et al. · Cureus · 4
PDF
Racial and Ethnic Differences in Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel or Ciltacabtagene Autoleucel
2024 · Lauren C. Peres, Alicia Richards, et al. · Blood · 2
PDF
Attrition after Referral for Chimeric Antigen Receptor T-Cell (CAR-T) Products in Multiple Myeloma (MM)
2023 · Naveen Subramanian, Ashwath Gurumurthi, et al. · Blood · 2
Association of genetic ancestry with outcomes and toxicity of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma
2026 · Christen M. Dillard, Hans Lee, et al. · Blood Cancer Journal · 1
PDF
Enhancing the Safety of Ciltacabtagene Autoleucel in Relapsed Multiple Myeloma (MM):Identification of Potentially Modifiable Risk-Factors Associated with Delayed Neurotoxicity and Non-Relapse Mortality
2026 · Surbhi Sidana, Brett Reid, et al. · Transplantation and Cellular Therapy · 1
Safety and efficacy of BCMA directed CAR-T therapy in older patients (Aged ≥ 75) with relapsed or refractory multiple myeloma (RRMM)
2025 · Arash Velayati, Alexandria Jensen, et al. · Blood · 1
PDF
Association between cilta-cel dose and efficacy and toxicity outcomes for patients with Relapsed/Refractory multiple myeloma (RRMM): A real-world analysis from the US multiple myeloma immunotherapy consortium
2025 · Ran Reshef, Alexandria Jensen, et al. · Blood · 1
PDF
Identifying candidates for outpatient administration of ciltacabtagene autoleucel (Cilta-cel) in relapsed-refractory multiple myeloma (RRMM)
2025 · Danai Dima, Lauren Peres, et al. · Blood · 1
Safety and Efficacy Outcomes for Patients with High-Risk Multiple Myeloma Receiving Idecabtagene Vicleucel: The MD Anderson Experience
2023 · Oren Pasvolsky, Michelle Hildebrandt, et al. · Blood · 1
PDF
CT-511 Clinical Characteristics and Response Outcomes in Older Multiple Myeloma Patients Who Received Idecabtagene Vicleucel: A Single Center Study
2022 · Nilesh Kalariya, Christopher Ferreri, et al. · Clinical Lymphoma Myeloma & Leukemia · 1
Abstract D078: Unlocking the vault: Can 2nd opinions by Comprehensive Cancer Center breast oncologists improve treatment quality for African Americans?
2020 · Rena J Pasick, Brittany Campbell, et al. · Cancer Epidemiology Biomarkers & Prevention · 1
When Myeloma Escapes the Bone Marrow: Extramedullary Disease in the Immunotherapy Era
2026 · Aimaz Afrough, Christen M. Dillard, et al. · Cancers
PDF
Duffy-null status and cytopenias following BCMA-directed CAR T therapy in multiple myeloma.
2026 · Christen Marie Dillard, Erneisha Brown, et al. · Journal of Clinical Oncology
Minimal Residual Disease Monitoring By Targeted Tracking Serum M-Protein Using Mass Spectrometry (EasyM) in Patients with Multiple Myeloma Receiving Ciltacabtagene Autoleucel
2026 · Oren Pasvolsky, Ruchi Singhal, et al. · Transplantation and Cellular Therapy
Early Relapse after Ciltacabtagene Autoleucel in High-Risk Multiple Myeloma: Implications for Risk-Adapted Therapy and Clinical Trial Design
2026 · Doris K. Hansen, Lauren C Peres, et al. · Transplantation and Cellular Therapy
Works count: 64
Citation count: 221
H-index: 7
I10-index: 6
Year
Topic
Type